Taspoglutide

Product Name: Taspoglutide

CAS No: 275371-94-3

Purity: 95%

Molar Mass: 3339.71

Chemical Formula: C152H232N40O45

Synonyms: DB14027, ITM077

Storage: Store at -20℃

Sequence: HXEGTFTSDVSSYLEGQAAKEFIAWLVKXR

Target: GLP-1 RA

Application: Taspoglutide (CAS: 275371-94-3) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes mellitus. As a GLP-1 receptor agonist, taspoglutide mimics the action of the endogenous hormone GLP-1, which is involved in regulating glucose homeostasis by stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and promoting satiety. By activating GLP-1 receptors, taspoglutide helps lower blood glucose levels, improve glycemic control, and reduce the risk of hyperglycemia in patients with type 2 diabetes. Taspoglutide is designed to have an extended duration of action, allowing for once-weekly dosing, which may improve patient adherence to treatment regimens. Clinical trials have demonstrated the efficacy of taspoglutide in reducing hemoglobin A1c levels and promoting weight loss in patients with type 2 diabetes, with a favorable safety profile.

Reference:

Rosenstock, J., Balas, B., Charbonnel, B., Bolli, G. B., Boldrin, M., Ratner, R., … & T-emerge 2 Study Group. (2013). The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes care, 36(3), 498-504.

Giraudon, M., Sturm, S., Lambert, N., Niggli, M., Brumm, J., Mangold, B., & Schmitt, C. (2017). Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide. Diabetes, Obesity and Metabolism, 19(4), 537-544.